Laboratory Corporation of America Holdings (LH) published its
2025 first and
2024 fourth quarter earnings, revealing mixed outcomes. Though
revenues missed estimates, earnings were reported to
exceed expectations. Expert opinions on LH's future prospects, split, are reflected in changes to price targets from various firms including
Morgan Stanley and Baird who raised their estimations, and B. Riley Financial who requisitioned a slight adjustment. The company is continually innovating its testing services, recently launching molecular residual disease and liquid biopsy solutions, and securing
3D liver models from Predictive Oncology. Beyond this, LH completed a strategic acquisition of select assets from BioReference Health and Invitae and is expanding its footprint in Japan and Singapore. Major executive shifts included the sale of significant shares by top executives and CFO Glenn Eisenberg announcing plans for retirement. Despite a bearish sentiment due to Q1 2025 results missing estimates, Labcorp still displays scalability, robustness, and growth potential in the biotech market.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 07 Jul 2020 07:00:00 GMT to Fri, 13 Jun 2025 00:24:22 GMT -
Rating 1
- Innovation 6
- Information 8
- Rumor 2
